Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 368

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)

Open access
Čelutkienė, Jelena, Pudil, Radek, López-Fernández, Teresa, Grapsa, Julia, Nihoyannopoulos, Petros, Bergler-Klein, Jutta, Cohen-Solal, Alain, Farmakis, Dimitrios, Tocchetti, Carlo Gabriele, von Haehling, Stephan, Barberis, Vassilis, Flachskampf, Frank A., Čeponienė, Indrė, Haegler-Laube, Eva, Suter, Thomas, Lapinskas, Tomas, Prasad, Sanjay, de Boer, Rudolf A., Wechalekar, Kshama, Anker, Markus S., Iakobishvili, Zaza, Bucciarelli-Ducci, Chiara, Schulz-Menger, Jeanette, Cosyns, Bernard, Gaemperli, Oliver, Belenkov, Yury, Hulot, Jean-Sébastien, Galderisi, Maurizio, Lancellotti, Patrizio, Bax, Jeroen, Marwick, Thomas H., Chioncel, Ovidiu, Jaarsma, Tiny, Mullens, Wilfried, Piepoli, Massimo, Thum, Thomas, Heymans, Stephane, Mueller, Christian, Moura, Brenda, Ruschitzka, Frank, Zamorano, Jose Luis, Rosano, Giuseppe, Coats, Andrew J.S., Asteggiano, Riccardo, Seferovic, Petar, Edvardsen, Thor, Lyon, Alexander R.·2020·European Journal of Heart Failure
DOI 10.1002/ejhf.1957
Open this paper in CoChat — free account

Abstract

Cardiovascular (CV) imaging is an important tool in baseline risk assessment and detection of CV disease in oncology patients receiving cardiotoxic cancer therapies. This position statement examines the role of echocardiography, cardiac magnetic resonance, nuclear cardiac imaging and computed tomography in the management of cancer patients. The Imaging and Cardio-Oncology Study Groups of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the ESC have evaluated the current evidence for the value of modern CV imaging in the cardio-oncology field. The most relevant echocardiographic parameters, including global longitudinal strain and three-dimensional ejection fraction, are proposed. The protocol for baseline pre-treatment evaluation and specific surveillance algorithms or pathways for anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor tyrosine kinase inhibitors, BCr-Abl tyrosine kinase inhibitors, proteasome inhibitors and immune checkpoint inhibitors are presented. The indications for CV imaging after completion of oncology treatment are considered. The typical consequences of radiation therapy and the possibility of their identification in the long term are also summarized. Special populations are discussed including female survivors planning pregnancy, patients with carcinoid disease, patients with cardiac tumours and patients with right heart failure. Future directions and ongoing CV imaging research in cardio-oncology are discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ejhf.1957

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 368

Metadata

Authors
Čelutkienė, J., Pudil, R., López-Fernández, T., Grapsa, J., Nihoyannopoulos, P., Bergler-Klein, J., Cohen-Solal, A., Farmakis, D., Tocchetti, C. G., von Haehling, S., Barberis, V., Flachskampf, F. A., Čeponienė, I., Haegler-Laube, E., Suter, T., Lapinskas, T., Prasad, S., de Boer, R. A., Wechalekar, K., Anker, M. S., Iakobishvili, Z., Bucciarelli-Ducci, C., Schulz-Menger, J., Cosyns, B., Gaemperli, O., Belenkov, Y., Hulot, J.-S., Galderisi, M., Lancellotti, P., Bax, J., Marwick, T. H., Chioncel, O., Jaarsma, T., Mullens, W., Piepoli, M., Thum, T., Heymans, S., Mueller, C., Moura, B., Ruschitzka, F., Zamorano, J. L., Rosano, G., Coats, A. J. S., Asteggiano, R., Seferovic, P., Edvardsen, T., & Lyon, A. R.
Venue
European Journal of Heart Failure
Publisher
Oxford University Press (OUP)
Published
2020-08-21
Volume
22
Issue
9
Pages
1504-1524
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
DOI
10.1002/ejhf.1957
OpenAlex
W3040275902
Cited by
368
References
7
FWCI
33.80
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). https://app.cochat.ai/papers/10.1002/ejhf.1957
The paper
Čelutkienė, J., Pudil, R., López-Fernández, T., Grapsa, J., Nihoyannopoulos, P., Bergler-Klein, J., Cohen-Solal, A., Farmakis, D., Tocchetti, C. G., von Haehling, S., Barberis, V., Flachskampf, F. A., Čeponienė, I., Haegler-Laube, E., Suter, T., Lapinskas, T., Prasad, S., de Boer, R. A., Wechalekar, K., . . . Lyon, A. R. (2020). Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). European Journal of Heart Failure. https://doi.org/10.1002/ejhf.1957

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.